References
- World Health Organization. Coronavirus Disease (COVID-19). Press Conference, 28 February 2020 [Internet]. [cited 2022 Feb 10]. Available from: https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-28feb2020.pdf?sfvrsn=13eeb6a4_2
- World Health Organization. WHO director-general’s opening remarks at the media briefing on COVID-19 - 11 March 2020 [Internet]. [cited 2022 Feb 10]. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19—11-march-2020
- Le TT, Cramer JP, Chen R, et al. Evolution of the COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020;19:667–668.
- US Food and Drug Administration. Emergency Use Authorization (EUA) for an unapproved product review memorandum. Application 27034 [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/media/144416/download
- US Food and Drug Administration. Emergency Use Authorization (EUA) for an unapproved product review memorandum. Application 27073 [Internet]. [cited 2022 Feb 10]. Available from: https://fda.report/media/144673/Moderna+COVID-19+Vaccine+review+memo.pdf
- US Food and Drug Administration. Emergency Use Authorization (EUA) for an unapproved product review memorandum. Application 27205 [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/media/146338/download
- Comirnaty SmPC. BioNTech manufacturing GmbH. Comirnaty SmPC. European medicines agency website [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/comirnaty-epar-product-information_en.pdf
- Vaxzevria SmPC. AstraZeneca AB. Vaxzevria SmPC. European medicines agency website [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf
- Spikevax SmPC. Moderna Biotech Spain S.L. Spikevax SmPC. European medicines agency website [Internet] [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf
- COVID-19 Vaccine Janssen SmPC. Janssen-Cilag International NV. COVID-19 vaccine Janssen SmPC. European medicines agency website [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-janssen-epar-product-information_en.pdf
- World Health Organization. WHO coronavirus (COVID-19) dashboard [Internet]. [cited 2022 Feb 10]. Available from: https://covid19.who.int/?gclid=CjwKCAjwo4mIBhBsEiwAKgzXOFGg4woTngtSuJSNB_cgi19enDLeCPhDJ6h_EmBvLeuAAknOhLICixoCrS4QAvD_BwE
- Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020;586:516–527.
- Ball P. The lightning-fast quest for COVID vaccines - and what it means for other diseases. Nature. 2021;589:16–18.
- S-B S, Chang H-L, Chen K-T. Current status of mumps virus infection: epidemiology, pathogenesis, and vaccine. Int J Environ Res Public Health. 2020;17. DOI:https://doi.org/10.3390/ijerph17051686.
- Piret J, Boivin G. Pandemics throughout history. Front Microbiol. 2020;11:631736.
- US Food and Drug Administration. Fast Track [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/fast-track
- European Medicines Agency. EMA initiatives for acceleration of development support and evaluation procedures for COVID-19 treatments and vaccines [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/other/ema-initiatives-acceleration-development-support-evaluation-procedures-covid-19-treatments-vaccines_en.pdf
- US Food and Drug Administration. Emergency use authorization of medical products and related authorities [Internet]. [cited 2022 Feb 10. Available from: https://www.fda.gov/media/97321/download
- European Medicines Agency. Conditional marketing authorization, report on ten years of experience at the European Medicines Agency [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/report/conditional-marketing-authorisation-report-ten-years-experience-european-medicines-agency_en.pdf
- US Food and Drug Administration. Emergency use authorization for vaccines to prevent COVID-19 - Guidance for Industry [Internet]. [cited 2022 Feb 10]. Available from 2022 Feb 10: https://www.fda.gov/media/142749/download
- European Medicines Agency. EMEA pandemic influenza crisis management plan for the evaluation and maintenance of pandemic influenza vaccines and antivirals [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/other/european-medicines-agency-pandemic-influenza-crisis-management-plan-evaluation-maintenance-pandemic_en.pdf
- Pandemrix SmPC. GlaxoSmithKline Biologicals. European Medicines Agency website [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/pandemrix-epar-product-information_en.pdf
- European Medicines Agency. Pandemic report and lessons learned [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/report/pandemic-report-lessons-learned-outcome-european-medicines-agencys-activities-during-2009-h1n1-flu_en.pdf
- US Food and Drug Administration. Medical countermeasures initiative [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/emergency-preparedness-and-response/medical-countermeasures-initiative-mcmi/about-mcmi
- Excler J-L, Saville M, Berkley S, et al. Vaccine development for emerging infectious diseases. Nat Med. 2021;27:591–600.
- ClinicalTrials.gov. Evaluation of the safety and immunogenicity of three consistency lots and a high-dose lot of rVSV-ZEBOV-GP (V920 Ebola Vaccine) in healthy adults (V920-012) [Internet]. [cited 2022 Feb 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT02503202
- US Food and Drug Administration. ERVEBO. BLA clinical review memorandum. [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/media/134270/download
- Jiang Z, Wang X, Xia J. Considerations on the clinical development of COVID-19 vaccine from trial design perspectives. Hum Vaccin Immunother. 2021;17:656–660.
- European Medicines Agency. COVID-19 guidance: research and development [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/guidance-developers-companies/covid-19-guidance-research-development
- European Medicines Agency. Mandate, objectives and rules of procedure of the COVID-19 EMA pandemic Task Force (COVID-ETF) [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/other/mandate-objectives-rules-procedure-covid-19-ema-pandemic-task-force-covid-etf_en.pdf
- Paul-Ehrlich-Institut. Accelerated procedures and processes in the COVID-19 pandemic [Internet]. [cited 2022 Feb 10]. Available from: https://www.pei.de/EN/newsroom/hp-news/2020/201118-bah-pei-dialogue-accelerated-procedures-covid-19.html?nn=164440.
- Iglesias-Lopez C. Temporary derogation of European environmental legislation for clinical trials of genetically modified organisms (GMOs) for COVID-19. Cytotherapy. 2021;23(1):10–11. DOI:https://doi.org/10.1016/j.jcyt.2020.09.005
- US Food and Drug Administration. Emergency use authorization for vaccines to prevent COVID-19 [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/emergency-use-authorization-vaccines-prevent-covid-19
- US Food and Drug Administration. Development and licensure of vaccines to prevent COVID-19 [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-and-licensure-vaccines-prevent-covid-19
- European Medicines Agency. Pharmacovigilance plan of the EU regulatory network for COVID-19 vaccines [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/other/pharmacovigilance-plan-eu-regulatory-network-covid-19-vaccines_en.pdf
- European Medicines Agency. FDA/EMA common commentary on submitting an initial Pediatric Study Plan (iPSP) and Paediatric Investigation Plan (PIP) for the prevention and treatment of COVID-19 [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/other/fda/ema-common-commentary-submitting-initial-paediatric-study-plan-ipsp-paediatric-investigation-plan_en.pdf
- European Medicines Agency. Advancing international collaboration on COVID-19 real-world evidence and observational studies [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/news/advancing-international-collaboration-covid-19-real-world-evidence-observational-studies
- European Medicines Agency. EMA considerations on COVID-19 vaccine approval [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/other/ema-considerations-covid-19-vaccine-approval_en.pdf
- International Coalition of Medicines Regulatory Authorities. Statement on COVID-19 [Internet]. [cited 2022 Feb 10]. Available from: http://www.icmra.info/drupal/en/covid-19
- US Food and Drug Administration. Summary of FDA & EMA global regulators meeting on data requirements supporting first-in-human clinical trials with SARS-CoV-2 vaccines [Internet].s [cited 2022 Feb 10]. Available from: https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/summary-fda-ema-global-regulators-meeting-data-requirements-supporting-first-human-clinical-trials
- European Medicines Agency. EMA’s governance during COVID-19 pandemic [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/emas-governance-during-covid-19-pandemic#working-with-eu-and-international-partners-section
- Friends of Cancer Research. COVID-19 evidence accelerator [Internet]. [cited 2022 Feb 10]. Available from: https://friendsofcancerresearch.org/covid19
- World Health Organization. What is the ACT-accelerator [Internet]. [cited 2022 Feb 10]. Available from: https://www.who.int/initiatives/act-accelerator/about
- International Federation of Pharmaceutical Manufacturers and Associations. COVID-19 R&D-based pharma industry’s innovative partnership allowed expedited vaccine development by sharing expertise, data and technology transfer, funding, and up-scaled manufacture to meet urgent global supply needs [Internet]. [cited 2022 Feb 10]. Available from: https://www.ifpma.org/wp-content/uploads/2021/03/IFPMA_Industrys-collaborations-on-COVID-vaccines-and-therapeutics-23.03.2021_V02.pdf
- Astrazeneca Press Releases. AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine[Internet]. [cited 2022 Feb 10]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-oxford-university-announce-landmark-agreement-for-covid-19-vaccine.html
- Moderna Press Releases. Moderna announces first participant dosed in NIH-led phase 1 study of mRNA vaccine (mRNA-1273) against novel coronavirus [Internet]. [cited 2022 Feb 10]. Available from: https://investors.modernatx.com/news/news-details/2020/Moderna-Announces-First-Participant-Dosed-in-NIH-led-Phase-1-Study-of-mRNA-Vaccine-mRNA-1273-Against-Novel-Coronavirus-03-16-2020/default.aspx
- Pfizer Press Release. Pfizer and BioNTech to co-develop potential COVID-19 vaccine [Internet]. [cited 2022 Feb 10]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-further-details-collaboration
- Pfizer Press Release. Pfizer and BioNTech announce Phase 3 trial data showing high efficacy of a booster dose of their COVID-19 vaccine [Internet]. [cited 2022 Feb 10]. Available from: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-phase-3-trial-data-showing
- BioNTech Press Releases. BioNTech and fosun pharma form COVID-19 vaccine strategic alliance in China [Internet]. [cited 2022 Feb 10]. Available from: https://investors.biontech.de/news-releases/news-release-details/biontech-and-fosun-pharma-form-covid-19-vaccine-strategic
- Yong CY, Ong HK, Yeap SK, et al. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front Microbiol. 2019;10:1781.
- Mendonça SA, Lorincz R, Boucher P, et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic. NPJ Vaccines. 2021;6:97.
- European Medicines Agency. Zabeno Summary of Product Characteristics [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/product-information/zabdeno-epar-product-information_en.pdf
- Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018;17:261–279.
- Sahin U, Karikó K, Ö T. mRNA-based therapeutics—developing a new class of drugs. Nat Rev Drug Discov. 2014;13:759–780.
- Hinz T, Kallen K, Britten CM, et al. The european regulatory environment of RNA-based vaccines. Methods Mol Biol. 2017;1499:203–222.
- Weide B, Pascolo S, Scheel B, et al. Direct injection of protamine-protected mRNA: results of a phase ½ vaccination trial in metastatic melanoma patients. J Immunother. 2009;32:498–507.
- Britten CM, Singh-Jasuja H, Flamion B, et al. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol. 2013;31:880–882.
- Vandeputte J, Saville M, and Cavaleri M, et al. IABS/CEPI platform technology webinar: is it possible to reduce the vaccine development time? Biologicals. 2021;71:55–60.
- Department of Health and Human Services, USA. Explaining operation warp speed [Internet]. [cited 2022 Feb 10]. Available from: https://health.mo.gov/living/healthcondiseases/communicable/novel-coronavirus-lpha/pdf/fact-sheet-operation-warp-speed.pdf
- The German Federal Ministry of Education and Research. German government funds three vaccine developers [Internet]. [cited 2022 Feb 10]. Available from: https://www.bundesregierung.de/breg-de/themen/buerokratieabbau/impfstofffoerderung-1772846
- The Coalition for Epidemic Preparedness Innovations. CEPI - Our Mission [Internet]. [cited 2022 Feb 10]. Available from: https://cepi.net/about/whyweexist/
- Lonza Press Releases. Moderna and Lonza announce worldwide strategic collaboration to manufacture moderna’s vaccine (mRNA-1273) against novel coronavirus [Internet]. [cited 2022 Feb 10]. Available from: https://www.lonza.com/news/2020-05-01-04-50
- Jackson NAC, Kester KE, Casimiro D, et al. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines. 2020;5:11.
- Zhan W, Muhuri M, Tai PWL, et al. Vectored immunotherapeutics for infectious diseases: can rAAVs be the game changers for fighting transmissible pathogens? Front Immunol. 2021;12:673699.
- European Commission. Memo. Framework contracts for pandemic influenza vaccines [Internet]. cited 2022 Feb 10]. Available from: https://ec.europa.eu/health/system/files/2019-03/ev_20190328_memo_en_0.pdf
- European Medicines Agency. Questions and answers on regulatory expectations for medicinal products for human use during the COVID-19 pandemic [Internet]. [cited 2022 Feb 10]. Available from: https://ec.europa.eu/health/sites/default/files/human-use/docs/guidance_regulatory_covid19_en.pdf
- World Health Organization. COVID-19 vaccine tracker and landscape [Internet]. [cited 2022 Feb 10]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process [Internet]. [cited 2022 Feb 10]. Available from: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_15July2021.pdf
- US Food and Drug Administration. FDA briefing document. EUA amendment request for Pfizer-BioNTech COVID-19 Vaccine for use in children 5 through 11 years of age [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/media/153447/download
- Paul-Ehrlich Institute. COVID-19 vaccine Vaxzevria (AstraZeneca) – review on scientific questions performed at EU level [Internet]. [cited 2022 Feb 10]. Available from: https://www.pei.de/EN/newsroom/hp-news/2021/210415-eu-covid-19-vaccine-vaxzevria-review-scientific-questions.html
- Science. Russia’s approval of a COVID-19 vaccine is less than meets the press release [Internet]. [cited 2022 Feb 10]. Available from: https://www.science.org/content/article/russia-s-approval-covid-19-vaccine-less-meets-press-release
- Kyriakidis NC, López-Cortés A, González EV, et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines. 2021;6:28.
- Callaway E. Russia’s fast-track coronavirus vaccine draws outrage over safety. Nature. 2020;584:334–335.
- Tanveer S, Rowhani-Farid A, Hong K, et al. Transparency of COVID-19 vaccine trials: decisions without data. BMJ Evid Based Med. 2021. DOI:https://doi.org/10.1136/bmjebm-2021-111735.
- World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issues interim policy recommendations [Internet]. [cited 2022 Feb 10]. Available from: https://www.who.int/news/item/01-06-2021-who-validates-sinovac-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations
- Levin EG, Lustig Y, Cohen C, et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N Engl J Med. 2021;385(24):e84.
- Centers for Disease Control and Prevention. SARS-CoV-2 variant classifications and definitions [Internet]. [ cited 2022 Feb 10]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-info.html
- Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–424.
- Emary KRW, Golubchik T, Aley PK, et al. Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet. 2021;397:1351–1362.
- Wall EC, Wu M, Harvey R, et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 delta VOC. Lancet. 2021;398:207–209.
- Wall EC, Wu M, Harvey R, et al. Neutralising antibody activity against SARS-CoV-2 VOCs B.1.617.2 and B.1.351 by BNT162b2 vaccination. Lancet. 2021;397:2331–2333.
- Moderna Press Releases. Moderna provides a clinical update on the neutralizing activity of its COVID-19 vaccine on emerging variants including the delta variant first identified in India [Internet]. [ cited 2022 Feb 10]. Available from: https://investors.modernatx.com/news/news-details/2021/Moderna-Provides-a-Clinical-Update-on-the-Neutralizing-Activity-of-its-COVID-19-Vaccine-on-Emerging-Variants-Including-the-Delta-Variant-First-Identified-in-India-06-29-2021/default.aspx
- Johnson and Johnson Press Releases. Positive New Data for Johnson & Johnson single-shot COVID-19 vaccine on activity against delta variant and long-lasting durability of response [Internet]. [ cited 2022 Feb 10]. Available from: https://www.jnj.com/positive-new-data-for-johnson-johnson-single-shot-covid-19-vaccine-on-activity-against-delta-variant-and-long-lasting-durability-of-response
- Ikegame S, Siddiquey M, Hung C-T, et al. Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Res Sq. 2021. DOI:https://doi.org/10.21203/rs.3.rs-400230/v1.
- ClinicalTrials.gov. Phase II/III study of AZD2816, for the prevention of COVID-19 in adults (AZD2816) [Internet]. [ cited 2022 Feb 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04973449?term=AZD2816&draw=2&rank=1
- ClinicalTrials.gov. A phase 3 study to evaluate the safety, tolerability, and immunogenicity of multiple production lots and dose levels of BNT162b2 RNA-Based COVID-19 vaccines against COVID-19 in healthy participants; 2021.
- ClinicalTrials.gov. A study to evaluate the immunogenicity and safety of mRNA-1273.211 vaccine for COVID-19 variants [Internet]. [ cited 2022 Feb 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04927065?term=NCT04927065&rank=1
- ClinicalTrials.gov. Delayed heterologous SARS-CoV-2 vaccine dosing (boost) after receipt of EUA vaccines [Internet]. [ cited 2022 Feb 10]. Available from: https://clinicaltrials.gov/ct2/show/NCT04889209
- US Food and Drug Administration. FDA authorizes booster dose of Pfizer-BioNTech COVID-19 vaccine for certain populations [Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/news-events/press-announcements/fda-authorizes-booster-dose-pfizer-biontech-covid-19-vaccine-certain-populations
- World Health Organization. WHO ad hoc consultation COVID vaccines methodological approaches to assess variants effect on vaccine efficacy, effectiveness and impact [Internet]. [cited 2022 Feb 10]. Available from: https://cdn.who.int/media/docs/default-source/documents/r-d-blueprint-meetings/blueprint-covid-vaccines-and-variants-research-methods.pdf?sfvrsn=27feead4_1&download=true
- US Food and Drug Administration. Coronavirus (COVID-19) update: FDA issues policies to guide medical product developers addressing virus variants[Internet]. [cited 2022 Feb 10]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-issues-policies-guide-medical-product-developers-addressing-virus
- European Medicines Agency. Reflection paper on the regulatory requirements for vaccines intended to provide protection against variant strain(s) of SARS-CoV-2 [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-regulatory-requirements-vaccines-intended-provide-protection-against-variant_en.pdf
- Koup RA, Donis RO, Gilbert PB, et al. A government-led effort to identify correlates of protection for COVID-19 vaccines. Nat Med. 2021;27:1493–1494.
- International Coalition of Medicines and Regulatory Authorities. ICMRA COVID-19 vaccine development: future steps Workshop [Internet]. [cited 2022 Feb 10]. Available from: http://www.icmra.info/drupal/covid-19/24june2021
- Australian Government Department of Health. Access consortium: alignment with ICMRA consensus on immunobridging for authorising new COVID-19 vaccines [Internet]. [cited 2022 Feb 10]. Available from: https://www.tga.gov.au/access-consortium-alignment-icmra-consensus-immunobridging-authorising-new-covid-19-vaccines
- Krause PR, Fleming TR, Longini IM, et al. SARS-CoV-2 variants and vaccines. N Engl J Med. 2021;385:179–186.
- European Medicines Agency. Procedural guidance for variant strain(s) update to vaccines intended for protection against human coronavirus [Internet]. [cited 2022 Feb 10]. Available from: https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/procedural-guidance-variant-strains-update-vaccines-intended-protection-against-human-coronavirus_en.pdf
- Maxmen A. The fight to manufacture COVID vaccines in lower-income countries. Nature. 2021;597:455–457.
- European Commission. An U.S.-EU agenda for beating the global pandemic: vaccinating the world, saving lives now, and building back better health security [Internet]. [cited 2022 Feb 10. Available from: https://ec.europa.eu/commission/presscorner/detail/en/statement_21_4846